AstraZeneca Pauses Plans for $271 Million Expansion of U.K. Site

Core Viewpoint - The company has decided to shelve plans for a research facility in Cambridge, following a previous decision to scrap an investment in Liverpool [1] Company Actions - The company has halted the development of a research facility in Cambridge [1] - This decision comes after the company canceled an investment project in Liverpool earlier in January [1]